Ovid Therapeutics Appoints New CEO
Ticker: OVID · Form: 8-K · Filed: 2024-08-02T00:00:00.000Z
Sentiment: neutral
Topics: leadership-change, ceo-appointment
TL;DR
Ovid Therapeutics just got a new CEO, Dr. Jeremy Levin. Big changes might be coming.
AI Summary
Ovid Therapeutics Inc. announced on July 30, 2024, a change in its board of directors. Dr. Jeremy Levin has been appointed as the new Chief Executive Officer and a member of the Board of Directors, effective immediately. Dr. Levin brings extensive experience in the biopharmaceutical industry.
Why It Matters
The appointment of a new CEO can signal a strategic shift or renewed focus for the company, potentially impacting its future development pipeline and market position.
Risk Assessment
Risk Level: medium — Leadership changes, especially at the CEO level, introduce uncertainty about future strategy and execution.
Key Players & Entities
- Ovid Therapeutics Inc. (company) — The company filing the report.
- Dr. Jeremy Levin (person) — Newly appointed Chief Executive Officer and Board Member.
- July 30, 2024 (date) — Effective date of the CEO appointment.
FAQ
Who is the new CEO of Ovid Therapeutics?
Dr. Jeremy Levin has been appointed as the new Chief Executive Officer of Ovid Therapeutics.
When did the new CEO appointment become effective?
The appointment of Dr. Jeremy Levin as CEO was effective immediately as of July 30, 2024.
What is Ovid Therapeutics' primary business?
Ovid Therapeutics Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the filing date of this 8-K report?
This 8-K report was filed on August 2, 2024.
Where is Ovid Therapeutics' principal executive office located?
Ovid Therapeutics' principal executive offices are located at 441 Ninth Avenue, 14th Floor, New York, New York 10001.
Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 13.1 · Accepted 2024-08-02 17:22:46
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share OVID The Nasdaq Stock Market
- $55,000 — ee payable for up to a total maximum of $55,000 over the course of the Consulting Perio
Filing Documents
- ovid-20240730.htm (8-K) — 27KB
- 0001628280-24-034481.txt ( ) — 151KB
- ovid-20240730.xsd (EX-101.SCH) — 2KB
- ovid-20240730_lab.xml (EX-101.LAB) — 22KB
- ovid-20240730_pre.xml (EX-101.PRE) — 13KB
- ovid-20240730_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OVID THERAPEUTICS INC. By: /s/ Jeffrey Rona Jeffrey Rona Chief Business and Financial Officer Dated: August 2, 2024